Generic Name and Formulations:
Trazodone HCl 50mg, 100mg, 150mg+, 300mg+; scored (+bi/trisected) tabs.
Various generic manufacturers
Indications for Trazodone:
≥18yrs: initially 150mg/day in divided doses with food. May increase by 50mg/day at 3–4 day intervals; max 400mg/day (outpatients) or 600mg/day (inpatients) in divided doses; give most of dose at bedtime.
<18yrs: not recommended.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening and unusual changes. Monitor for serotonin syndrome or NMS-like reactions; discontinue if occurs. Screen for bipolar disorder. Pre-existing cardiovascular disease (monitor). Acute post MI: not recommended. Risk of QT prolongation esp. in hypokalemia, hypomagnesemia, or genetic disposition. Angle-closure glaucoma. Predisposition to priapism; discontinue if occurs. Renal and hepatic impairment. Volume-depleted. Mania/hypomania. Psychosis. Epilepsy. Avoid ECT. Write ℞ for smallest practical amount. Reevaluate periodically. Elderly. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant during or within 14 days of MAOIs. Increased risk of serotonin syndrome with other serotonergics (eg, SSRIs, SNRIs, triptans) and drugs that impair serotonin metabolism (eg, MAOIs, antipsychotics, dopamine antagonists). Concomitant tryptophan: not recommended. Concomitant QT-prolonging drugs or CYP3A4 inhibitors may increase risk of cardiac arrhythmias. Increased risk of bleeding with concomitant NSAIDs, aspirin, or others that affect coagulation; monitor. Potentiates alcohol, other CNS depressants, barbiturates, digoxin, phenytoin, antihypertensives. Potentiated by potent CYP3A4 inhibitors (eg, nefazodone, ritonavir, indinavir, ketoconazole, itraconazole); consider reducing trazodone dose. Antagonized by potent CYP3A4 inducers (eg, carbamazepine); may need dose adjustments. Discontinue before general anesthetics, if possible.
Somnolence/sedation, dizziness, constipation, blurred vision, dry mouth, syncope, arrhythmias, hypotension, nausea, fatigue, headache, hyponatremia (esp. in elderly).
Formerly known under the brand name Desyrel.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- To Improve Healthcare Policy, Congress Needs More Physicians
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- The Ethical Argument Against Publishing Medical Research: What Responsibility Do Journal Editors Have?
- Poll: Should Migraineurs Avoid Headache Triggers?